PMID- 34484872
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 10
IP  - 1
DP  - 2021
TI  - Differential infection of murine and human dendritic cell subsets by oncolytic 
      vesicular stomatitis virus variants.
PG  - 1959140
LID - 10.1080/2162402X.2021.1959140 [doi]
LID - 1959140
AB  - Oncolytic viruses (OVs) can eradicate tumor cells and elicit antitumor immunity. 
      VSV-GP, a chimeric vesicular stomatitis virus (VSV) with the glycoprotein (GP) of 
      the lymphocytic choriomeningitis virus, is a promising new OV candidate. However, 
      the interaction of VSV-GP with host immune cells is not fully understood. 
      Dendritic cells (DCs) are essential for inducing efficient antitumor immunity. 
      Thus, we aimed to investigate the interaction of VSV-GP with different murine and 
      human DCs subsets in direct comparison to the less cytopathic variant VSV-dM51-GP 
      and wild type VSV. Immature murine bone marrow-derived DCs (BMDCs) were equally 
      infected and killed by VSV and VSV-GP. Human monocyte-derived DCs (moDCs) were 
      more permissive to VSV. Interestingly, VSV-dM51-GP induced maturation instead of 
      killing in both BMDCs and moDCs as well as a pronounced release of 
      pro-inflammatory cytokines. Importantly, matured BMDCs and moDCs were no longer 
      susceptible to VSV-GP infection. Mouse splenic conventional DC type 1 (cDC1) 
      could be infected ex vivo by VSV and VSV-GP to a higher extent than cDC2. 
      Systemic infection of mice with VSV-GP and VSV-dM51-GP resulted in strong 
      activation of cDCs despite low infection rates in spleen and tumor tissue. Human 
      blood cDC1 were equally infected by VSV and VSV-GP, whereas cDC2 showed 
      preferential infection with VSV. Our study demonstrated differential DC 
      infection, activation, and cytokine production after the treatment with VSV and 
      VSV-GP variants among species and subsets, which should be taken into account 
      when investigating immunological mechanisms of oncolytic virotherapy in mouse 
      models and human clinical trials.
CI  - (c) 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Pipperger, Lisa
AU  - Pipperger L
AUID- ORCID: 0000-0001-7150-3586
AD  - Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
FAU - Riepler, Lydia
AU  - Riepler L
AD  - Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
FAU - Kimpel, Janine
AU  - Kimpel J
AD  - Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
FAU - Siller, Anita
AU  - Siller A
AD  - Central Institute of Blood Transfusion and Immunology, University Hospital 
      Innsbruck, Innsbruck, Austria.
FAU - Stoitzner, Patrizia
AU  - Stoitzner P
AUID- ORCID: 0000-0002-8488-6704
AD  - Department of Dermatology, Venereology & Allergology, Medical University of 
      Innsbruck, Innsbruck, Austria.
FAU - Banki, Zoltan
AU  - Banki Z
AUID- ORCID: 0000-0002-3826-5800
AD  - Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
FAU - von Laer, Dorothee
AU  - von Laer D
AD  - Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210831
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
SB  - IM
MH  - Animals
MH  - Dendritic Cells
MH  - Humans
MH  - Mice
MH  - *Oncolytic Virotherapy
MH  - *Oncolytic Viruses/genetics
MH  - *Vesicular Stomatitis
MH  - Vesicular stomatitis Indiana virus/genetics
PMC - PMC8409795
OTO - NOTNLM
OT  - Oncolytic viruses
OT  - dendritic cells
OT  - infection
OT  - vesicular stomatitis virus
COIS- No potential conflicts of interest were disclosed.
EDAT- 2021/09/07 06:00
MHDA- 2021/10/16 06:00
PMCR- 2021/08/31
CRDT- 2021/09/06 06:03
PHST- 2021/09/06 06:03 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/08/31 00:00 [pmc-release]
AID - 1959140 [pii]
AID - 10.1080/2162402X.2021.1959140 [doi]
PST - epublish
SO  - Oncoimmunology. 2021 Aug 31;10(1):1959140. doi: 10.1080/2162402X.2021.1959140. 
      eCollection 2021.